Cited by 141Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Milligan, Donald W., Wheatley, Keith, Littlewood, Timothy, Craig, Jenny I. O., Burnett, Alan K., for the NCRI Haematological Oncology Clinical Studies Group·2006·Blood

DOI 10.1182/blood-2005-10-4202

Open this paper in CoChat — free account

Abstract

The optimum chemotherapy schedule for reinduction of patients with high-risk acute myeloid leukemia (relapsed, resistant/refractory, or adverse genetic disease) is uncertain. The MRC AML (Medical Research Council Acute Myeloid Leukemia) Working Group designed a trial comparing fludarabine and high-dose cytosine (FLA) with standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE). Patients were also randomly assigned to receive filgrastim (G-CSF) from day 0 until neutrophil count was greater than 0.5 × 109/L (or for a maximum of 28 days) and all-trans retinoic acid (ATRA) for 90 days. Between 1998 and 2003, 405 patients were entered: 250 were randomly assigned between FLA and ADE; 356 to G-CSF versus no G-CSF; 362 to ATRA versus no ATRA. The complete remission rate was 61% with 4-year disease-free survival of 29%. There were no significant differences in the CR rate, deaths in CR, relapse rate, or DFS between ADE and FLA, although survival at 4 years was worse with FLA (16% versus 27%, P = .05). Neither the addition of ATRA nor G-CSF demonstrated any differences in the CR rate, relapse rate, DFS, or overall survival between the groups. In conclusion these findings indicate that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA.

Integrity signals

Registry

Crossref · 10.1182/blood-2005-10-4202

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission
Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Lazarus, H. M., Rowe, J. M., Paietta, E. M., Willman, C. L., Hurd, D. D., Bennett, J. M., Blume, K. G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392301 · Cited by 607
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial
Burnett, A. K., Goldstone, A. H., Stevens, R., Hann, I. M., Rees, J. K. H., Gray, R. G., & Wheatley, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09214-3 · Cited by 560
Self-citation
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., de Greef, G. E., Jacky, E., der Lelie, J. V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 510
Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., & Schiffer, C. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322503 · Cited by 447
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 437
Self-citation
A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
Wheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 432
Self-citation
Acute promyelocytic leukemia: evolving therapeutic strategies
Tallman, M. S., Nabhan, C., Feusner, J. H., & Rowe, J. M. (2002) · Blood · doi:10.1182/blood.v99.3.759 · Cited by 395

Show all 49 references

Research works printed but not linked: 1

Visani G, Tosi P, Zinzani PL, et al. FLAG: an effective and tolerable protocol for the treatment of “poor-risk” acute myeloid leukemia. Leukemia. 1994;8: 1842-1846.

Sorted by citations

Items 101–141 of 141

Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia
Montillo, M., Ricci, F., Tedeschi, A., Cafro, A. M., Nosari, A., Nichelatti, M., Marbello, L., & Morra, E. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.12.014 · Cited by 7
The blind men and the AML elephant: can we feel the progress?
Tauro, S. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.33 · Cited by 6
Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia
Khorashad, J. S., Rizzo, S., & Tonks, A. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.125 · Cited by 5
Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions
Rosenblat, T. L., & Jurcic, J. G. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.007 · Cited by 6
The ATRA-21 gene-expression model predicts retinoid sensitivity in CEBPA double mutant, t(8;21) and inv(16) AML patients
Bolis, M., Terao, M., Pattini, L., Garattini, E., & Fratelli, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0241-5 · Cited by 5
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML
Ambinder, A. J., Norsworthy, K. J., Hernandez, D., Palau, L., Paun, B. C., Duffield, A. S., Chandraratna, R., Sanders, M. E., Varadhan, R., Jones, R. J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587062 · Cited by 5
The Hematopoietic Growth Factors in Acute Leukemia: A European Perspective
Heuser, M., Ganser, A., & Hoelzer, D. F. (2010) · Cancer treatment and research · doi:10.1007/978-1-4419-7073-2_19 · Cited by 5
Autophagy Inhibition–induced Cytosolic DNA Sensing Combined with Differentiation Therapy Induces Irreversible Myeloid Differentiation in Leukemia Cells
Baba, T., Tomaru, U., Hirao, A., Mukaida, N., & Johmura, Y. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0507 · Cited by 4
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia
Gurion, R., Belnik, Y., Gafter‐Gvili, A., Paul, M., Vidal, L., Ben‐Bassat, I., Shpilberg, O., & Raanani, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008238.pub2 · Cited by 4
Enlarged PML-nuclear bodies trigger conflicting cell cycle signal-mediated cytotoxicity in leukemia cells
Baba, T., Kumamoto, S., Moriguchi, Y., Morishita, S., Hirao, A., & Johmura, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07911-7 · Cited by 3
Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation
Ramsey, H. E., Stengel, K. R., Pino, J. C., Johnston, G., Childress, M. A., Gorska, A. E., Arrate, M. P., Fuller, L., Villaume, M. T., Fischer, M. A., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00830-5 · Cited by 3
Leukaemia update. Part 2: managing patients with leukaemia in the community
Grigoropoulos, N., Petter, R., Veer, M. B. V., Scott, M. A., & Follows, G. (2013) · BMJ · doi:10.1136/bmj.f1932 · Cited by 2
Homoharringtonine and granulocyte colony-stimulating factor priming for acute myeloid leukemia: is it ready for prime time?
Ustwani, O. A., & Wetzler, M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.776169 · Cited by 2
Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience
Auberger, J., Clausen, J., Willenbacher, W., Erdel, M., Gunsilius, E., Petzer, A. L., Gastl, G. A., & Nachbaur, D. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0084-5 · Cited by 2
Increased mortality with FLA compared with ADE chemotherapy in high-risk AML
Lane, S., Marlton, P. V., & Mollee, P. N. (2006) · Blood · doi:10.1182/blood-2006-06-032680 · Cited by 2
Primer caso de leucemia mieloide aguda tratado en Cuba con altas dosis de antraciclinas en la inducción
Cruz, C. H., Quintana, A. N., Fraga, Y. R., Uría, J. C., Medina, R. C., & Pérez, I. M. (2012) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Cytogenetic and Molecular Aberrations as Predictive Biomarkers in Acute Myeloid Leukemia
Heeg, S., & Waller, C. F. (2012) · Springer eBooks · doi:10.1007/978-1-4419-9755-5_6 · Cited by 1
Potential Role for All- trans Retinoic Acid in Nonpromyelocytic Acute Myeloid Leukemia
Ma, H. S., Robinson, T. M., & Small, D. (2016) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2016-0015 · Cited by 1
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
Najima, Y., Maeda, T., Kamiyama, Y., Nakao, S., Ozaki, Y., Nishio, H., Tsuchihashi, K., Ichihara, E., Miumra, Y., Endo, M., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02461-4 · Cited by 1
Adaptación del esquema IDA-FLAG en el Instituto Nacional de Cancerología: experiencia valiosa
Rosales, C. (2014) · Revista Colombiana de Cancerología · doi:10.1016/j.rccan.2014.07.001 · Cited by 1
DNA damage response and anti-apoptotic proteins expression in NPMc+ mutated cells in acute myeloid leukaemia
Qutob, H. M. H. (2014) · Nottingham ePrints (University of Nottingham)
Management of acute myeloid leukemia
Burnett, A. K. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781926.002
Self-citation
Leukemias and plasma cell dyscrasias
Wiernik, P. H. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.07.002
Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
Jagt, R. H. C. V. D. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.008
Acute myeloid leukaemia - therapy - past, present and future
Faduola, P., Hakim, A. J., Mansnérus, J., Imai, A., & Neill, R. O. (2013) · Translational Biomedicine
Use of rHuG-CSF for the Treatment of Myeloid Leukemia and in Targeting Leukemia Stem Cells
Ishikawa, F. (2011) · Springer eBooks · doi:10.1007/978-3-0348-0218-5_9
The role of aldehyde dehydrogenase (ALDH) isoform 1A3 in the pathogenesis of human acute myeloid leukemia (AML)
So, C.-Y. (2011) · doi:10.5353/th_b4633935
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults:
Tallman, M. S., Löwenberg, B., Bloomfield, C. D., Grimwade, D. J., Larson, R. A., Naoe, T., Niederwieser, D. W., Ossenkoppele, G. J., Sanz, M. Á., Dohner, J., et al. (2010)
Self-citation
Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia
Longu, F., Fozza, C., Dessì, L., Longinotti, M., Bonfigli, S., Careddu, M. G., Coppola, L., Giannico, B., Nieddu, R., Podda, L., et al. (2016) · Acta Haematologica · doi:10.1159/000449277
Therapeutic management of acute myeloid leukemia
Fiegl, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-26772-2_5
[Study of the effects and mechanism of all-trans retinoic acid on leukemic cell line U937 cells with NPM1 mutation].
Qiu, S., Wan, Y. L., Jia, Y., Rao, Q., Wang, M., & Wang, J. X. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.10.008
Efficacy of platelet transfusions
Kerkhoffs, J. (2012) · Leiden Repository (Leiden University)
Current Awareness in Hematological Oncology
(2007) · Hematological Oncology · doi:10.1002/hon.795
Cytosolic DNA sensing combined with differentiation therapy induces irreversible differentiation and cell growth arrest in myeloid leukemia cellsPreprint
Baba, T., Tomaru, U., Hirao, A., Mukaida, N., & Johmura, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2047508/v1
Cytosolic DNA sensing combined with differentiation therapy induces irreversible differentiation and cell growth arrest in myeloid leukemia cellsPreprint
Baba, T., Tomaru, U., Hirao, A., Mukaida, N., & Johmura, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2047508/v2
Data from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2023) · doi:10.1158/1078-0432.c.6530669
Data from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2023) · doi:10.1158/1078-0432.c.6530669.v1
Cytosolic DNA sensing combined with differentiation therapy induces irreversible differentiation and cell growth arrest in myeloid leukemia cellsPreprint
Baba, T., Tomaru, U., Hirao, A., Mukaida, N., & Johmura, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2047508/v3
Role of the SUMO pathway in Acute Myeloid Leukemias response to treatments
Baik, H. (2017) · theses.fr (ABES) · doi:10.70675/156a7d66zb325z4965zbd18z8c101e88ebc2
Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study
Namdaroğlu, S., Kakci, M., Şenol, B., Öztürk, O. C., Şeker, Ö., Uğur, M. C., FENER, N. G., Başçı, S., & Batgi, H. (2026) · Cancers · doi:10.3390/cancers18193132
Recombinant hematopoietic growth factors in acute myeloid leukemia
Gang, M., Gale, R. P., & Walter, R. B. (2026) · Leukemia · doi:10.1038/s41375-026-03158-z

Authors: Milligan, D. W., Wheatley, K., Littlewood, T., Craig, J. I. O., Burnett, A. K., & for the NCRI Haematological Oncology Clinical Studies Group
Affiliations: John Radcliffe Hospital (GB)
ORCID: Wheatley, Keith
Burnett, Alan K.
Venue: Blood
Publisher: American Society of Hematology
Published: 2006-06-15
Volume: 107
Issue: 12
Pages: 4614-4622
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2005-10-4202
OpenAlex: W1984229644
Cited by: 141
References: 49
Citations by year: 2026: 2 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 10 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 11 · 2015: 10 · 2014: 7 · 2013: 8 · 2012: 8
FWCI: 5.26
Type: journal article
Language: en
Open access: closed
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: high-risk acute myeloid leukemia, fludarabine, cytarabine, daunorubicin, etoposide, filgrastim, granulocyte colony-stimulating factor, all-trans retinoic acid, reinduction chemotherapy, complete remission, disease-free survival, relapse
MeSH terms: Filgrastim, Adolescent, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Daunorubicin, Etoposide, Female, Humans, Male, Middle Aged, Recombinant Proteins, Remission Induction, Retrospective Studies, Risk Factors, Tretinoin, Leukemia, Myeloid, Acute, Survival Rate, Granulocyte Colony-Stimulating Factor, Treatment Outcome, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks